Searched for: in-biosketch:true
person:bangas01
Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials
Bangalore, Sripal; Kumar, Sunil; Volodarskiy, Alexander; Messerli, Franz H
CONTEXT: Most guidelines for treatment of hypertension including the Joint National Committee-7 recommend a blood pressure (BP) goal of <140/90 mm Hg for hypertensive patients and a more aggressive goal of <130/80 mm Hg for patients with coronary artery disease (CAD), based largely on expert consensus. OBJECTIVE: To evaluate the BP targets in patients with CAD DATA SOURCES: PUBMED, EMBASE and CENTRAL Study Selection: Randomised clinical trials (RCTs) of antihypertensive therapy in patients with CAD, enrolling at least 100 patients, with achieved systolic pressure of <=135 mm Hg in the 'intensive BP' group and <=140 mm Hg in the 'standard BP' group with follow-up for at least 1 year and evaluating cardiovascular outcomes. DATA EXTRACTION: The following efficacy outcomes were extracted- all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, heart failure and revascularisation. RESULTS: We identified 15 RCTs enrolling 66 504 participants with 276 328 patient-years of follow-up. Intensive BP group (=135 mm Hg) was associated with a 15% decrease in heart failure rate and 10% decrease in stroke rate, driven largely by trials with a more intensive BP group (=130 mm Hg), with similar outcomes for death and cardiovascular death and was associated with a 105% increase in the risk of hypotension. More intensive BP group (=130 mm Hg) was also associated with a reduction in myocardial infarction and angina pectoris. The results were similar in a Bayesian random effects model. In addition, lower seemed to be better (based on regression analysis) for the outcomes of myocardial infarction, stroke, heart failure and perhaps angina. CONCLUSIONS: The present body of evidence suggests that in patients with CAD, intensive systolic BP control to =135 mm Hg and possibly to =130 mm Hg is associated with a modest reduction in stroke and heart failure but at the expense of hypotension. Lower was better, although not consistently so for myocardial infarction, stroke, heart failure and perhaps angina. Further trials are needed to prove these findings.
PMID: 22914531
ISSN: 1355-6037
CID: 218632
Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert
Messerli, Franz H; Bangalore, Sripal; Torp-Pedersen, Christian; Staessen, Jan A; Kostis, John B
PMID: 22815329
ISSN: 0195-668x
CID: 218642
Heart rate in coronary artery disease: should we lower it?
Axsom, Kelly; Bangalore, Sripal
OPINION STATEMENT: Elevated resting heart rate is an independent risk factor for cardiovascular morbidity and mortality in patients with and without coronary artery disease. In patients with known coronary artery disease, elevated heart rate reduces diastolic filling time and increases cardiac workload, resulting in supply demand mismatch with consequent ischemia and angina. While lower heart rate is associated with better prognosis, it is not known if pharmacological reduction in heart rate is beneficial and if heart rate is merely a marker for increased risk and worse outcomes. Certainly, physiologically lower resting heart rate as attained by exercise improves morbidity and mortality. While physiological reduction in heart rate is mainly a manifestation of increased parasympathetic drive, pharmacological reduction of heart rate with beta-blockers is mediated via the sympathetic pathway and associated with mixed outcomes. In addition, beta-blockers have other cardiovascular effects (lowering blood pressure), are metabolically active, and it is unknown if the beneficial effects (if any) are mediated via reduction in heart rate versus other cardiovascular effects. Ivabradine is a new medication that lowers heart rate selectively by inhibiting the I(f) current without other cardiovascular effects, offering for the first time a therapeutic agent that selectively targets heart rate. The medication has shown promise in early trials in patients with heart failure, but it is unclear if this agent will be beneficial in patients with stable coronary artery disease without heart failure.
PMID: 23104638
ISSN: 1092-8464
CID: 213922
How and when to decide on revascularization in stable ischemic heart disease
Mecklai, Alicia; Bangalore, Sripal; Hochman, Judith
OPINION STATEMENT: Coronary artery disease is the leading cause of death and disability worldwide. While an invasive strategy of early revascularization reduces cardiovascular morbidity and mortality in patients with acute coronary syndromes, there is no convincing evidence that this strategy leads to an incremental survival advantage for patients with stable ischemic heart disease (SIHD) beyond that achieved by optimal medical therapy. Two landmark trials, COURAGE and BARI 2D, suggest that a strategy of aggressive medical therapy is a reasonable initial approach to such patients. However, there remain certain groups of patients, those with at least moderate ischemia on baseline stress testing, where there is still clinical equipoise. Major society guidelines favor revascularization based on observational data and trials of CABG conducted decades ago, yet data from modern randomized trials are lacking. Ongoing trials such as ISCHEMIA should provide clinicians with evidence to guide selection of the appropriate initial management strategy for patients with SIHD.
PMID: 23143818
ISSN: 1092-8464
CID: 213952
The reply [Letter]
Messerli, Franz H; Bangalore, Sripal
ORIGINAL:0010469
ISSN: 0002-9343
CID: 1901662
Drug-eluting versus bare-metal coronary stents: where are we now?
Amoroso, Nicholas S; Bangalore, Sripal
Drug-eluting stents have dramatically reduced the risk of restenosis, but concerns of an increased risk of stent thrombosis have provided uncertainty about their use. Recent studies have continued to show improved procedural and clinical outcomes with drug-eluting stents both in the setting of acute coronary syndromes and stable coronary artery disease. Newer generation drug-eluting stents (especially everolimus-eluting stents) have been shown to be not only efficacious but also safe with reduced risk of stent thrombosis when compared with bare-metal stents, potentially changing the benchmark for stent safety from bare-metal stents to everolimus-eluting stents. While much progress is being made in the development of bioabsorbable polymer stents, nonpolymer stents and bioabsorbable stent technology, it remains to be seen whether these stents will have superior safety and efficacy outcomes compared with the already much improved rates of revascularization and stent thrombosis seen with newer generation stents (everolimus-eluting stents and resolute zotarolimus-eluting stents).
PMID: 24236469
ISSN: 2042-6305
CID: 641592
Statin therapy for secondary prevention: is there a gender difference? Test for interaction in meta-analysis revisited [Letter]
Bangalore, Sripal; Messerli, Franz H
PMID: 23102233
ISSN: 0002-9149
CID: 218622
Cardiovascular death and cancer death--competing risk? [Letter]
Messerli, Franz H; Bangalore, Sripal
PMID: 22578909
ISSN: 0002-9149
CID: 218652
Anomalous right coronary artery and sudden cardiac death
Greet, Brian; Quinones, Adriana; Srichai, Monvadi; Bangalore, Sripal; Roswell, Robert O
PMID: 23250555
ISSN: 1941-3084
CID: 204082
Effectiveness of Fluoroscopy-Save versus Cinematography at Reducing Radiation Exposure During Diagnostic Coronary Angiography: A Randomized Controlled Trial [Meeting Abstract]
Shah, Binita; Mai, Xingchen; Tummala, Lakshmi; Kliger, Chad; Feit, Frederick; Bangalore, Sripal; Liou, Michael; Attubato, Michael; Coppola, John; Slater, James
ISI:000310210101128
ISSN: 0735-1097
CID: 185732